IP Library Granted Patent US 9,517,277
Granted Patent B2
US 9,517,277 · App. 14/128,238 · Granted Dec 13, 2016

Immune-stimulating photoactive hybrid nanoparticles

Inventors: Shanta Dhar (Athens, GA); Joshua Choi (Athens, GA); Sean Marrache (Athens, GA)
Assignee: University of Georgia Research Foundation, Inc.
A61K47/48915A61K41/0071
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,517,277
App. No.
14/128,238
Granted
Dec 13, 2016
Kind
B2
Abstract

Provides is a therapeutic technology that combines the phototoxic and immune-stimulating ability of photodynamic therapy with the widespread effectiveness of the immune system to reduce the viability of such as cancer cells and tumors. The nanoparticle compositions of the disclosure combine an immunostimulant with a photosensitizer using a nanoparticle delivery platform. For example, zinc pthalocyanine, which is a long-wavelength absorbing photosensitizer, integrated into a polymeric nanoparticle core made up of poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG). The outside surface of the core can be coated with metallic nanoparticles, which are then modified with CpG-ODN. Metastatic mouse breast carcinoma cells showed significant photocytotoxicity of the hybrid after irradiation with a 660 nm LASER light and this activity was remarkably better than either treatment alone. Treatment of mouse bone marrow derived dendritic cells with the photodynamic therapy-killed 4T1 cell lysate showed that the combination of photodynamic therapy with a synergistic immunostimulant in a single nanoparticle system resulted in an immune response suitable for the treatment of such as a metastatic cancer.

Claims (5)

1. A multifunctional hybrid nanoparticle, comprising a nanoparticle core comprising a photosensitizer and a polymer, a plurality of metallic nanoparticles disposed on the surface of the nanoparticle core, and an immunostimulant disposed on the plurality of metallic nanoparticles, wherein the photosensitizer is zinc phthalocyanine, the nanoparticle core comprises a biodegradable polymer of poly (D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol), the metallic nanoparticles are gold nanoparticles, and the immunostimulant disposed on the metallic nanoparticles is a CpG-ODN.

2. A method of reducing the viability of a cell comprising the steps of:

(i) administering to an animal or human subject a pharmaceutically acceptable composition comprising a multifunctional hybrid nanoparticle comprising a nanoparticle core comprising a photosensitizer and a polymer, a plurality of metallic nanoparticles disposed on the surface of the nanoparticle core; and an immunostimulant disposed on the metallic nanoparticles, and wherein the immunostimulant generates an immune response in the animal or human subject that reduces the viability of a cancerous cell or a tumor, wherein the photosensitizer is zinc phthalocyanine, the nanoparticle core comprises a biodegradable polymer of poly (D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol), the metallic nanoparticles are gold nanoparticles, and the immunostimulant disposed on the metallic nanoparticles is a CpG-ODN; and

(ii) irradiating the cell with a light energy having a wavelength generating a photoacitvated oxygen species by the photosensitizer.

3. A pharmaceutically acceptable composition comprising a multifunctional hybrid nanoparticle comprising a nanoparticle core comprising a photosensitizer and a polymer; a plurality of a metallic nanoparticle disposed on the surface of the nanoparticle core; and an immunostimulant disposed on the surfaces of the plurality of metallic nanoparticles, wherein the photosensitizer is zinc pthalocyanine, the nanoparticle core comprises a biodegradable polymer of poly (D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol), the metallic nanoparticles are gold nanoparticles, and the immunostimulant disposed on the metallic nanoparticles is CpG-ODN; and a pharmaceutically acceptable carrier.

Assignments (3)
CONFIRMATORY LICENSE Recorded Feb 26, 2014
From: UNIVERSITY OF GEORGIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032334/0684 →
CONFIRMATORY LICENSE Recorded Feb 26, 2014
From: UNIVERSITY OF GEORGIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032334/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2013
From: DHAR, SHANTA; CHOI, JOSHUA; MARRACHE, SEAN
To: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
Reel/Frame 031830/0157 →
Continuity (2)
Provisional Application 61508242 · Jul 15, 2011
Related Publication 20140220143A1 · Aug 7, 2014